Funds holding Immix Biopharma Inc
ISIN US45258H1068 · United States
- Fund holders
- 24
- Of which ETFs
- 1 23 other funds
- Value held
- 50.8M $
- Share of capital
- 7.8 % of 71.5M shares on Aug 3, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST | 2,549,019 | 23.2M $ | 1.46 % | 3.56 % | as of Mar 31, 2026 ↗ |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1,285,595 | 11.7M $ | 0.00 % | 1.80 % | as of Mar 31, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 456,667 | 4.2M $ | 0.01 % | 0.64 % | as of Mar 31, 2026 ↗ |
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 357,034 | 3.2M $ | 0.31 % | 0.50 % | as of Apr 30, 2026 ↗ |
| T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC. | 326,401 | 3M $ | 0.03 % | 0.46 % | as of Mar 31, 2026 ↗ |
| Timber Point Global Allocations Fund 360 Funds | 120,000 | 1.1M $ | 3.69 % | 0.17 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 115,751 | 934.1K $ | 0.00 % | 0.16 % | as of Feb 28, 2026 ↗ |
| iShares Micro-Cap ETF iShares Trust | 86,999 | 792.6K $ | 0.07 % | 0.12 % | as of Mar 31, 2026 ↗ |
| Ultra-Small Company Fund Bridgeway Funds, Inc. | 80,000 | 728.8K $ | 0.85 % | 0.11 % | as of Mar 31, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 38,012 | 306.8K $ | 0.00 % | 0.05 % | as of Feb 28, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 30,412 | 245.4K $ | 0.00 % | 0.04 % | as of Feb 28, 2026 ↗ |
| Schwab Total Stock Market Index Fund SCHWAB CAPITAL TRUST | 27,392 | 244.6K $ | 0.00 % | 0.04 % | as of Apr 30, 2026 ↗ |
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS | 22,835 | 208K $ | 0.00 % | 0.03 % | as of Mar 31, 2026 ↗ |
| VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS | 22,585 | 205.7K $ | 0.00 % | 0.03 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Health Sciences Portfolio T. ROWE PRICE EQUITY SERIES, INC. | 20,000 | 182.2K $ | 0.03 % | 0.03 % | as of Mar 31, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 16,844 | 135.9K $ | 0.00 % | 0.02 % | as of Feb 28, 2026 ↗ |
| Small Cap Core Fund Northern Funds | 15,008 | 136.7K $ | 0.04 % | 0.02 % | as of Mar 31, 2026 ↗ |
| Multi-Manager U.S. Small Cap Equity Fund Goldman Sachs Trust II | 10,622 | 94.9K $ | 0.03 % | 0.01 % | as of Apr 30, 2026 ↗ |
| Health Sciences Trust John Hancock Variable Insurance Trust | 7,200 | 65.6K $ | 0.03 % | 0.01 % | as of Mar 31, 2026 ↗ |
| 1290 VT Micro Cap Portfolio EQ Advisors Trust | 6,161 | 56.1K $ | 0.03 % | 0.01 % | as of Mar 31, 2026 ↗ |
| EQ/T.Rowe Price Health Sciences Portfolio EQ Advisors Trust | 5,000 | 45.6K $ | 0.03 % | 0.01 % | as of Mar 31, 2026 ↗ |
| Victory Extended Market Index Fund Victory Portfolios III | 4,545 | 40.6K $ | 0.01 % | 0.01 % | as of Apr 30, 2026 ↗ |
| Total Stock Market Index Trust John Hancock Variable Insurance Trust | 629 | 5.7K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Knights of Columbus U.S. ALL CAP INDEX FUND ADVISORS' INNER CIRCLE III | 218 | 1.9K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Timber Point Global Allocations Fund 360 Funds | 3.69 % | as of Mar 31, 2026 ↗ |
| Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST | 1.46 % | as of Mar 31, 2026 ↗ |
| Ultra-Small Company Fund Bridgeway Funds, Inc. | 0.85 % | as of Mar 31, 2026 ↗ |
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 0.31 % | as of Apr 30, 2026 ↗ |
| iShares Micro-Cap ETF iShares Trust | 0.07 % | as of Mar 31, 2026 ↗ |
| Small Cap Core Fund Northern Funds | 0.04 % | as of Mar 31, 2026 ↗ |
| 1290 VT Micro Cap Portfolio EQ Advisors Trust | 0.03 % | as of Mar 31, 2026 ↗ |
| Health Sciences Trust John Hancock Variable Insurance Trust | 0.03 % | as of Mar 31, 2026 ↗ |
| EQ/T.Rowe Price Health Sciences Portfolio EQ Advisors Trust | 0.03 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Health Sciences Portfolio T. ROWE PRICE EQUITY SERIES, INC. | 0.03 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 24 | +8 | 5,604,929 | +34.7 % |
| 2026Q1 | 16 | +6 | 4,159,519 | +385.5 % |
| 2025Q4 | 10 | 0 | 856,793 | -7.9 % |
| 2025Q3 | 10 | -1 | 930,443 | +3.4 % |
| 2025Q2 | 11 | +2 | 899,712 | +1.8 % |
| 2025Q1 | 9 | 0 | 884,015 | +0.9 % |
| 2024Q4 | 9 | 0 | 876,430 | +13.2 % |
| 2024Q3 | 9 | -6 | 774,569 | +25.9 % |
| 2024Q2 | 15 | +5 | 615,362 | +129.7 % |
| 2024Q1 | 10 | 0 | 267,915 | +40.9 % |
| 2023Q4 | 10 | 190,109 |
Institutional managers
74 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 4,802,002 | 43.7M $ | as of Mar 31, 2026 |
| Saturn V Capital Management LP | 3,693,585 | 33.6M $ | as of Mar 31, 2026 |
| EVENTIDE ASSET MANAGEMENT, LLC | 2,549,019 | 23.2M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 1,750,200 | 15.9M $ | as of Mar 31, 2026 |
| MARSHALL WACE, LLP | 1,641,552 | 15M $ | as of Mar 31, 2026 |
| Logos Global Management LP | 1,225,000 | 11.2M $ | as of Mar 31, 2026 |
| Bleichroeder LP | 1,000,000 | 9.1M $ | as of Mar 31, 2026 |
| FRANKLIN RESOURCES INC | 969,066 | 8.8M $ | as of Mar 31, 2026 |
| Velan Capital Investment Management LP | 740,000 | 6.7M $ | as of Mar 31, 2026 |
| Blue Owl Capital Holdings LP | 547,552 | 5M $ | as of Mar 31, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 471,394 | 4.3M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 468,377 | 4.3M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 463,384 | 4.2M $ | as of Mar 31, 2026 |
| LGT Fund Management Co Ltd. | 416,594 | 3.8M $ | as of Mar 31, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 415,001 | 3.8K $ | as of Mar 31, 2026 |
| GREAT POINT PARTNERS LLC | 350,000 | 3.2M $ | as of Mar 31, 2026 |
| Institute for Wealth Management, LLC. | 337,552 | 3.1M $ | as of Mar 31, 2026 |
| Burkehill Global Management, LP | 294,118 | 2.7M $ | as of Mar 31, 2026 |
| KVP Capital Advisors, LP | 230,423 | 2.1M $ | as of Mar 31, 2026 |
| J. Goldman & Co LP | 228,089 | 2.1M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 191,910 | 1.7M $ | as of Mar 31, 2026 |
| Qube Research & Technologies Ltd | 187,675 | 1.7M $ | as of Mar 31, 2026 |
| SEI INVESTMENTS CO | 147,140 | 1.3M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 139,886 | 1.3M $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 138,232 | 1.3M $ | as of Mar 31, 2026 |
Declared shareholders of Immix Biopharma Inc
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 13.00 % | 9,090,732 | as of May 29, 2026 · SCHEDULE 13G |
| Millennium Management LLC and 2 others | 3.30 % | 1,750,200 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding Immix Biopharma Inc". https://titelia.com/en/stocks/immix-biopharma-inc-US45258H1068